See more : Clarim Acquisition Corp. (CLRM) Income Statement Analysis – Financial Results
Complete financial analysis of Sierra Oncology, Inc. (SRRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sierra Oncology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Lifestyle Communities Limited (LCOMF) Income Statement Analysis – Financial Results
- Norte Grande S.A. (NORTEGRAN.SN) Income Statement Analysis – Financial Results
- China Coal Energy Company Limited (1898.HK) Income Statement Analysis – Financial Results
- APL Apollo Tubes Limited (APLAPOLLO.BO) Income Statement Analysis – Financial Results
- Shian Yih Electronic Industry Co.,Ltd (3531.TWO) Income Statement Analysis – Financial Results
Sierra Oncology, Inc. (SRRA)
About Sierra Oncology, Inc.
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 67.15M | 45.12M | 53.25M | 41.08M | 30.16M | 33.90M | 26.36M | 19.08M | 2.84M |
| General & Administrative | 27.44M | 20.12M | 13.74M | 14.34M | 12.46M | 14.18M | 9.47M | 3.50M | 1.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.44M | 20.12M | 13.74M | 14.34M | 12.46M | 14.18M | 9.47M | 3.50M | 1.16M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 94.59M | 65.24M | 66.99M | 55.42M | 42.62M | 48.08M | 35.83M | 22.58M | 4.01M |
| Cost & Expenses | 94.59M | 65.24M | 66.99M | 55.42M | 42.62M | 48.08M | 35.83M | 22.58M | 4.01M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.72M |
| Depreciation & Amortization | 305.00K | 238.00K | 83.00K | 111.00K | 258.00K | 197.00K | 111.00K | 12.00K | 1.00K |
| EBITDA | -94.36M | -80.52M | -88.35M | -53.53M | -41.60M | -47.53M | -53.09M | -23.86M | -4.11M |
| EBITDA Ratio | 0.00% | -26,840.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -94.66M | -64.94M | -66.99M | -55.42M | -42.62M | -48.08M | -35.83M | -22.58M | -4.01M |
| Operating Income Ratio | 0.00% | -21,647.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -15.82M | -21.44M | 1.78M | 760.00K | 351.00K | -17.38M | -1.29M | -2.83M |
| Income Before Tax | -94.66M | -80.76M | -88.44M | -53.64M | -41.86M | -47.72M | -53.21M | -23.87M | -6.83M |
| Income Before Tax Ratio | 0.00% | -26,920.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -3.00K | 142.00K | -160.00K | -302.00K | 156.00K | 143.00K | 55.00K | 2.00K | -108.00K |
| Net Income | -94.66M | -80.90M | -88.28M | -53.34M | -42.02M | -47.87M | -53.26M | -23.87M | -6.83M |
| Net Income Ratio | 0.00% | -26,967.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.14 | -7.70 | -30.30 | -30.16 | -33.68 | -63.32 | -147.95 | -56.76 | -13.19 |
| EPS Diluted | -7.14 | -7.70 | -30.30 | -30.16 | -33.68 | -63.32 | -147.95 | -56.76 | -13.19 |
| Weighted Avg Shares Out | 13.25M | 10.51M | 2.91M | 1.77M | 1.25M | 756.01K | 359.99K | 420.57K | 518.10K |
| Weighted Avg Shares Out (Dil) | 13.25M | 10.51M | 2.91M | 1.77M | 1.25M | 756.01K | 359.99K | 420.57K | 518.10K |
Sierra Oncology Soars After Takeover by Glaxo
Why Sierra Oncology Stock Is Soaring Today
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
Why GlaxoSmithKline (GSK) Is Buying Sierra Oncology (SRRA) For $1.9 Billion
GlaxoSmithKline to buy Sierra Oncology for $1.9 billion
GSK to buy Sierra Oncology for $1.9 billion
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
Sierra Oncology: Plenty Of Room To Trade Higher After Latest Myelofibrosis Data
Source: https://incomestatements.info
Category: Stock Reports